Display options
Cite
Behrendt V, Hilberg O, Bakker V, et al. [Asthma treatment in general practice]. Ugeskr Laeger. 2022;184(2)
Behrendt, V., Hilberg, O., Bakker, V., Ulrik, C. S., Bjerring, N., & Ottesen, A. L. (2022). [Asthma treatment in general practice]. Ugeskrift for laeger, 184(2), .
Behrendt, Victor, et al. "[Asthma treatment in general practice]." Ugeskrift for laeger vol. 184,2 (2022).
Behrendt V, Hilberg O, Bakker V, Ulrik CS, Bjerring N, Ottesen AL. [Asthma treatment in general practice]. Ugeskr Laeger. 2022 Jan 10;184(2). Danish. PMID: 35023469.
Copy Download .nbib Format: NLM
Share it on

Ugeskr Laeger. 2022 Jan 10;184(2).

[Asthma treatment in general practice].

Ugeskrift for laeger

[Article in Danish]
Victor Behrendt, Ole Hilberg, Vibeke Bakker, Charlotte Suppli Ulrik, Niels Bjerring, Anders Løkke Ottesen

Affiliations

  1. Medicinsk Afdeling, Sygehus Lillebælt, Vejle Sygehus.
  2. Afdeling for Øre-Næse-Halskirurgi, Københavns Universitetshospital - Rigshospitalet.
  3. TrygFondens Center for Aktiv Sundhed.
  4. Lungemedicinsk Afdeling, Københavns Universitetshospital - Amager Hvidovre Hospital.
  5. Lungemedicinsk Afdeling, Odense Universitetshospital.

PMID: 35023469

Abstract

This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.

Publication Types